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Abstract
Background: Troponin is a valuable and highly used marker for 
the assessment of the myocardial damage. Elevated tro ponin 
levels are the result of myocardial injury irrespective of etiology. 
Aim: Evaluation of dynamics of troponin I changes in the first 
days (since “0” to 3rd day) after heart transplantation (HTX).
Material and methods: Retrospective analysis of 42 patients 
aged 21 to 62 years, average age 47.4 ±12.4. Study group 
consisted of the patients which hearts were harvested by two 
surgeons according to the identical protection scheme using 
CELSIOR cardioplegic solution. In all patients troponin I levels 
in the following days after HTX were measured.
Dynamics of troponin I changes was assessed, using the one-
step immunoenzymatic test (normal values to 0.1 ng/ml) in all 
of the patients in the first days after HTX. The highest daily 
value was taken into the analysis.
Results: Average troponin I levels in the subsequent days after 
HTX were as follows: 21.7 ±22.1; 21.3 ±22.5; 17.6 ±20.3; 13.2 ±15.3 
ng/ml. Based on ANOWA (Kruskal-Wallisa) test statistically 
significant troponin I levels decrease in the consecutive days 
after HTX (p = 0.0002) was noted. The biggest decrease was 
observed between days “0” and “3” and between days “1” 
and “3” (respectively: 54.1 and 53.7%); the smallest decreased 
appeared between days “0” and “1” after HTX (0.7%).
Conclusion: Immediately after HTX significantly elevated 
troponin I levels can be observed that could be connected with 
perioperative myocardial injury caused by the heart harvesting 
and transplantation.
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Streszczenie
Wstęp: Troponina I jest wiarygodnym i powszechnie stosowa-
nym markerem uszkodzenia mięśnia serca. Zwiększenie stęże-
nia troponiny jest wynikiem uszkodzenia mięśnia serca o różnej 
etiologii.
Cel: Ocena dynamiki zmian stężeń troponiny I w pierwszych 
dobach (od 0. do 3. doby włącznie) po przeszczepieniu serca 
(ang. heart transplantation – HTX).
Materiał i metody: Analizą retrospektywną objęto 42 chorych 
w wieku od 21 do 62 lat, średnio 47,4 ±12,4. Badaną grupę 
stanowili pacjenci, których serca pobierało dwóch chirurgów 
wg identycznego schematu protekcji z zastosowaniem kar-
diopleginy CELCIOR i u których zmierzono stężenia troponiny 
I w kolejnych dobach po HTX.
Oceniono dynamikę zmian stężenia troponiny I oznaczanej 
metodą jednostopniowego testu immunoenzymatycznego 
(norma od 0,1 ng/ml) w identyczny sposób u wszystkich cho-
rych, w pierwszych dobach po HTX. W przypadku więcej niż 
jednego poziomu oznaczanego w ciągu doby do analizy brano 
najwyższą wartość uzyskaną w danej dobie. 
Wyniki: Średnie stężenie troponiny I w kolejnych dobach po HTX 
wyniosło kolejno: 21,7 ±22,1; 21,3 ±22,5; 17,6 ±20,3; 13,2 ±15,3 ng/ml. 
Na podstawie testu ANOVA (Kruskal-Wallisa) stwierdzono istotne 
statystycznie zmniejszenie stężenia tropiny I w kolejnych dobach 
po HTX (p 0,0002). Największy spadek zanotowano pomiędzy 
dobą 0. i 3. oraz pomiędzy dobą 1. i 3. (odpowiednio: 54,1 i 53,7%), 
a najmniejszy spadek pomiędzy 0. i 1. dobą po HTX (0,7%).
Wnioski: Bezpośrednio po transplantacji serca obserwuje się 
znacz nie zwiększone stężenia troponiny I, zmniejszające się istot-
nie w kolejnych dobach, co może świadczyć o obecnym urazie 
okołooperacyjnym związanym z pobraniem i przeszczepieniem 
serca.
Słowa kluczowe: przeszczep serca, troponina, serce dawcy.
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Background
Despite intensive development of the new surgical 
and pharmacological options of the end-stage cardiac 
failure treatment, heart transplantation (HTX) still remains 
a necessary and successful method. Even facing the lack 
of control studies, HTX seems to significantly increase 
survival, exercise capacity, return to work, and quality of 
life in comparison to conventional treatment. According to 
European Society of Cardiology (ESC) Guidelines, HTX has the 
first class of recommendation with level of evidence C [1].
Half-life time in adult cardiac recipients gradually in-
creases since the first successful HTX operations. Recently 
about 50% of the patients survive more than 10 years. 
However early mortality about 10-20% appears still high, 
especially when compared with classical cardiac surgery pro-
cedures. The most frequent direct cause of death between 
“0” and 3rd days post HTX is graft failure that makes more 
than 40% of all-cause mortality in that period. In front of 
chronic heart donors lack, more and more often “marginal 
donors” have to be accepted for transplantation. Older donor 
age, impaired donor cardiac function or longer ischemic time 
may potentially increase risk of early graft failure [2].
Analysis of the damage markers in the transplanted 
heart early after heart transplantation seems valuable.
Troponin is built in between of actin filaments and is 
bounded with tropomiozin C. It is functionally connected 
with contraction of skeletal muscles (and, what is more 
important, heart muscle). Its structure has been described 
as the complex of three proteins. 
From among three troponin subunits (C, I, T), very 
sensitive and recognized marker of the heart damage is 
troponin I that connected with actin and stabilized troponin–
tropomiozin complex. Increased troponin level points not 
only for myocardial infarction (as described in the guidelines 
for the diagnosis of myocardial infarction) but also allows 
for evaluation of myocardial injury expanse irrespectively of 
its etiology [3]. 
Troponin seems to be a valuable marker for the 
assessment of the extension and dynamics of the potential 
damage of the transplanted heart. 
The aim of the study was evaluation of troponin I levels 
dynamics in the first days after HTX (“0” to 3rd day).
Material and methods
Material
Retrospective analysis contained 42 patients (4 female, 
38 male) in the age 21 to 62 years, average 47.4 ±12.4 years. 
Study group consisted of the patients which hearts were 
harvested by two surgeons (two of the authors) according 
to the same protection scheme with the use of CELSIOR 
cardioplegic solution. Troponin I levels in the first and the 
following days after HTX were measured.
Methods
Dynamics of changes in the troponin I levels was eva-
luated. Troponin I level was measured in all of the patients 
using the method of one-stage immunoenzymatic test 
(normal up to 0.1 ng/ml). The highest value obtained during 
the same day was taken into the statistical analysis.
Myocardial protection 
CELSIOR is the cardioplegic solution and it was 
always used for the donor heart protection. The main 
components of the solution are the following: Mannitol, 
Lactobionic acid, Glutamic acid, Histidine, Calcium chloride, 
Potassium chloride (15 mmol), Magnesium chloride. The 
solution is sli ghtly alkaline (pH = 7.3), slightly hypertonic 
(242-368 mOsmol/l) with low viscosity (1.15 cSt), and has 
a high buffering capacity (acidic approximately 11 mmol, 
alkaline approximately 7 mmol).
During harvesting the donor heart was arrested with 
2 litres of CELSIOR cardioplegic solution given directly into 
aortic bulb. Simultaneously the heart was cooled by the cold 
physiological solution with crashed ice, given directly into 
the donor pericardium. After excision of the heart, the third 
litre of cardioplegic solution CELCIOR was given into aortic 
bulb. During transport the heart was placed in the same 
cardioplegic solution in temperature of 10 degrees Celsius. 
The fourth litre of CELCIOR was infused directly after 
unpacking the heart and directly before the implantation.
Statistical techniques 
Statistical analysis was performed using STATISTICA 
8.0 software. First, type of the variables distribution was 
assessed with basic statistical packages. Because all the 
analysed parameters had the distribution distant from 
the normal one, non-parametric tests were used. Non-
parametric ANOVA Kruskal Walis variation analysis was 
utilized. Results were described as arithmetic averages 
with statistical deviation. P < 0.05 was considered as sta-
tis ti cally significant.
Results
The average troponin I level in the consecutive days 
after HTX was as follows: starting from 21.7 ±22.1 ng/ml in 
“0” day to 13.2 ±15.3 ng/ml in 3rd day (Table I, Fig. 1).
Based on ANOVA test (Kruskal-Wallis) the statistically 
significant decrease of troponin I levels was described in 
the following days after HTX (p = 0.0002). The biggest 
decrease was noted between “0” and “3” days (54.1%), the 
smallest one appeared between “0” and “1” days after HTX 
(0.7%) (Table II).
Discussion
The process of cardiomyocyte lesion during ischemia 
is complex. Deficiency of substrates and oxygen impairs 
ATP turn over. Activation of glycolysis leads (through anae-
robic processes) to intracellular acidosis. In the next step 
the following processes can be observed: ionic distur-
bances, inflammation, phospholipases activation and 
increase in synthesis of thromboxan A2 or PAF (platelet 
activating factor). The consequences of these processes are 
cardiomyocytes lesion, their necrosis and manifestation of 
necrotic markers.
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The ideal marker of ischemia should have the following 
features:
•  fast release from the cell in the amount proportional to 
the extent of injury,
•  occurrence only in the definite tissues (e.g. cardio myo­
cytes), 
•  high concentration [4]. 
There are at least several ischemic myocardial injury 
markers (creatine phosphokinase and its isoenzymes, apar-
tate aminotransferase, lactatet dehydrogenaze, mioglobin, 
troponin). However, it is the troponin, that seems to be 
an ideal and the most objective ischemia markers re-
commended by National Academy of Clinical Biochemistry 
(NACB) and the latest guidelines of ESC [4­6].
Our data shows the very high levels of troponin I in the 
first days after HTX. Statistical analysis show the highest 
troponin level directly after HTX, which significantly 
decrease in the following 3 days.
There is only limited data concerning troponin levels 
analysis after HTX. Zimmerman et al. in 1993 described the 
group of 19 patients after HTX, which troponin T levels up 
to 90 days after HTX were studied. 
In contradistinction to our results showing the highest 
troponin I levels in “0” day after HTX gradually decreasing 
to 3rd day, the authors observed consistently increasing 
troponin T levels with maximum value on 7th day. Moreover, 
they noted elevated troponin T levels through the following 
weeks au to the 3rd month after HTX. Troponin values 
are impossible to compare because of different types 
of troponin (I and T) used [7]. Similarly to Zimmermann 
et al., Halwachs et al. during examining 15 patients after 
HTX observed the highest levels of troponin T between 3rd 
and 14th day after HTX. Additionally, the authors observed 
statistically significant influence of pulmonary hypertension 
in the transplanted patient, but not total ischemic time on 
troponin levels [8]. 
Labarrere et al. demonstrated the significant influence 
troponin released after heart transplantation on long-term 
operation results. In the group of 110 patients after HTX 
they observed elevated troponin I levels in the half of the 
patients in the 12-month follow-up. In comparison with 
the control population (undetectable troponin levels) these 
patients had significantly higher risk of vasculopathy and 
late graft failure [9]. 
Elevated troponin levels was also connected with acute 
cardiac rejection of the transplanted heart. Siaplaouras 
et al. demonstrated that troponin I is not a sensitive but 
a specific marker of acute rejection in children [10].
The literature as well as the own experience emphasize 
the important role of the troponin levels after HTX moni-
toring. Prolongation of control period for troponin levels 
up to at least 12 months seems useful. It can allow more 
complex and proper analysis of the long-term transplanted 
heart function.
Study limitation:
•  retrospective analysis based on archive data,
•  limited study group,
•  impossibility of explicit comparison with the literature 
due to analysis of different troponin types (I or T),
•  replacement of troponin I (used before) by highly sensi­
tive troponin T (in 2010) in the authors` centre, that 
complicates further analysis.
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Fig. 1. Analysis of troponin level decrease in the following days 
after HTX 
(trop0 – troponin I “0” day; trop1 – troponin I 1st day, trop2 – troponin I 2nd day, 
trop3 – troponin I 3rd day after HTX)
ANOVA Kruskal-Wallis test; p = 0.0002
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Table I. Average troponin I levels in the consecutive days after HTX 
(trop0 – troponin I “0” day; trop1 – troponin I 1st day, trop2 – tropo-
nin I 2nd day, trop3 – troponin I 3rd day after HTX)
Average value (ng/ml) Standard deviation (± SD)
Trop0 21.7 22.1
Trop1 21.3 22.5
Trop2 17.6 20.3
Trop3 13.2 15.3
Table II. Analysis of the percentage decrease of troponin I levels 
in the following days after HTX (trop0 – troponin I “0” day; trop1 – 
troponin I 1st day, trop2 – troponin I 2nd day, trop3 – troponin I 3rd 
day after HTX)
Percentage of change
Trop0 – Trop1 –0.7
Trop1 – Trop2 –30.9
Trop2 – Trop3 –33.0
Trop0 – Trop2 –31.5
Trop1 – Trop3 –53.7
Trop0 – Trop3 –54.1
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The study was conducted with the approval of Local 
Bioethical Committee (KBET/224/B/2010).
Conclusion
Immediately after heart transplantation significantly 
elevated troponin I levels can be observed, with subsequent 
significant decrease that could demonstrate perioperative 
injury connected with harvesting and heart transplantation. 
To the 3rd day (examined period) after HTX significantly 
elevated troponin I levels could be still noted. 
Praca zaprezentowana na X Jubileuszowym Kongresie 
Polskiego Towarzystwa Transplantacyjnego w Hotelu Ossa 
koło Rawy Mazowieckiej, 9–11.06.2011 r.
W ramach realizacji grantu K/ZDS/002427 MNiSW 
(UJCM).
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